Abstract
Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.
Original language | English |
---|---|
Pages (from-to) | 511-514 |
Number of pages | 4 |
Journal | Journal of Neuromuscular Diseases |
Volume | 7 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- immune-checkpoint inhibitors
- immune-correlated adverse events
- inflammatory myopathy
- Pembrolizumab
- pulmonary carcinoma
ASJC Scopus subject areas
- Neurology
- Clinical Neurology